间充质干细胞治疗支气管肺发育不良研究进展被引量：4

Advances on mesenchymal stem cells in the treatment of bronchopulmonary dysplasia

导出

摘要支气管肺发育不良（BPD）是早产儿最常见的慢性肺部疾病,目前仍缺乏有效的治疗方法.近年来,动物研究发现间充质干细胞（MSCs）可通过定向增殖分化、旁分泌及免疫调节的机制对高氧介导的肺损伤发挥促进肺泡上皮修复、减轻肺部炎症的作用,对BPD有一定疗效.此外,已有临床试验显示MSCs治疗BPD是安全可行的,并提示对BPD的恢复有促进作用,为根本性治疗BPD带来了希望.现结合MSCs的生物学特性,对其应用于BPD的动物实验、临床试验及作用机制、存在问题的国内外研究进展作一综述. Bronchopulmonary dysplasia（BPD）is the most common chronic respiratory disease in premature in-fants,there is a lack of effective treatment now. In recent years,animal studies showed that treatment of mesenchymal stem cells （MSCs）can ameliorate hyperoxia-induced lung injury by promoting the restoration of alveolar epithelium and reducing the inflammation of lung through regeneration,paracrine and immunomodulatory,moreover,there has been a clinical trial shows that MSCs in the treatment of BPD is safe and feasible. Which may benefit the recovery of BPD and bring a hope for radical treatment of BPD. Now,focusing on the biological characteristics of MSCs,the mechanism and application of MSCs in the treatment of BPD in animal models and clinical trials as well as the existing problems in the latest research were reviewed.

作者犹景贻舒畅符州 You Jingyi;Shu Chang;Fu zhou(Department of Respiratory,Children＇s Hospital of Chongqing Medical University,Chongqing 400014,China)

机构地区重庆医科大学附属儿童医院呼吸科

出处《中华实用儿科临床杂志》 CSCD 北大核心 2018年第16期1267-1270,共4页 Chinese Journal of Applied Clinical Pediatrics

基金国家自然科学基金（30700915）

关键词间充质干细胞细胞治疗支气管肺发育不良 Mesenchymal stem cell Cell therapy Bronchopulmonary dysplasia

分类号 R722.6 [医药卫生—儿科]

引文网络
相关文献

参考文献1

1梁穗新,王一飞,何少茹.早产儿生理性支气管肺发育不良研究进展[J].中华实用儿科临床杂志,2016,31(2):158-160. 被引量：11

二级参考文献31

1McEvoy CT,Jain L,Schmidt B,et al. Bronchopulmonary Dysplasia:NHL- BI Workshop on the Primary Prevention of Chronic Lung Diseases [J]. Ann Am Thorac Soc, 2014,11 (Suppl 3 ) :S146 - 153.
2Poindexter BB, Feng R, Schmidt B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program[J]. Ann Am Thorac Soc,2015, [Epub a-head of print].
3Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following res- pirator therapy of hyaline-membrane disease. Bronchopulmonary dyspla- sia[J]. N Engl J Med, 1967,276 (7):357 -368.
4Jobe AH, Bancalari E. Bronehopulmonary dysplasia [J]. Am J Respir Crit Care Med,2001,163(7) :1723 - 1729.
5Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates [J]. Pediatrics,2004,114 (5) : 1305 - 1311.
6Poindexter BB, Jobe AH. The diagnostic conundrum of bronchopulmonary dysplasia[J]. J Pediatr, 2015,167 ( 3 ) : 517 - 518.
7Maitre NL, Ballard RA, Ellenberg JH, et al. Respiratory consequences of prematurity : evolution of a diagnosis and development of a comprehensive approach[J]. J Perinatol,2015,35 (5) :313 - 321.
8Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants:prediction from oxygen requirement in the neonatal period[J]. Pediatrics,1988,82(4) :527 -532.
9Simpson SJ, Hall GL, Wilson AC. Lung function following very preterm birth in the era of "new" bronehopulmonary dysplasia[J]. Respirology, 2015,20 (4) :535 - 540.
10Islam JY, Keller RL, Aschner JL, et al. Understanding the short and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med,2015,192 (2) : 134 - 156.